AIM: To investigate the change of myopic choroidal neovascularization treated by ranibizumab and evaluate their value in monitoring the effect of anti- vascular endothelial growth factor(VEGF)therapy.

METHODS: The study enrolled 30 patients(30 eyes)diagnosed with myopic choroidal neovascularization. All affected eyes were treated with intravitreal ranibizumab 0.05mL(10mg/mL). Best corrected visual acuity(BCVA), non-contact tonometer, ophthalmoscope, fundus fluorescein angiograph(FFA)and OCTA were evaluated monthly until 6mo. The changes of BCVA and central macular thickness(CMT)were compared at 1, 3 and 6mo after treatment.

RESULTS: All patients received an average of 1.70±0.65 injections. BCVA was 0.96±0.17(LogMAR)before therapy, and BCVA 1, 3 and 6mo after treatment respectively improved by 0.23±0.09, 0.34±0.07, 0.38±0.11. The differences were significant(t=5.461, 8.191, 8.894; P<0.05). Mean CMT decreased form 281.07±13.72μm to 261.33±13.13μm, 243.47±16.65μm, 234.73±17.52μm respectively 1, 3 and 6mo after treatment, showing significant differences(t=12.007, 13.360, 9.531; P<0.05). OCTA revealed a progressively smaller vascular lesion and reduction in capillary density.

CONCLUSION: Intravitreal ranibizumab for CNV secondary to pathologic myopia is effective and safe; OCTA is a noninvasive and time-saving new technology, and it also is a promising tool for clinicians to make preliminary diagnosis and assess treatment efficacy in the follow-up visits.